News

Filter

Current filters:

Researchledipasvir

Impressive data for once-daily sofosbuvir and ledipasvir treatment of HCV genotype 1

12-04-2014

Strong results from three Phase III clinical trials (ION-1, ION-2 and ION-3) evaluating the investigational…

Anti-viralsBiotechnologyGilead SciencesledipasvirResearchsofosbuvirSovaldi

Gilead's 1st-qtr profits rocket 63% on 11% revenue rise; moves forward with hep C program

03-05-2013

US biotech firm Gilead Sciences (Nasdaq: GILD) has reported that revenues for the first quarter of 2013…

Anti-viralsBiotechnologyFinancialGilead SciencesledipasvirResearchsofosbuvir

Enrollment in Gilead's ION-1 study continues following planned DSMB review

26-03-2013

US HIV/AIDS and antiviral drugs specialist Gilead Sciences (Nasdaq: GILD) has provided a positive update…

Anti-viralsBiotechnologyGilead SciencesledipasvirResearchsofosbuvir

Back to top